Product Information
COTEMPLA XR-ODT 17.3 MG TABLET is a brand product labeled by Neos Therapeutics Brands, LLC, priced at $17.8934 per EA under NDC 70165020030. Its NADAC has been published 455 times since Jan 17, 2018.
FDA first approved this application on Jun 19, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Methylphenidate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
17.3 mg/1
Manufacturer
Neos Therapeutics Brands, LLCNDC
70165020030
Classification
Brand
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATEApproval Type
New Drug (NDA)
FDA Application
NDA205489FDA Approved
6/19/2017
TE Code
AB
On Market Since
6/20/2017
Pharmacological Classes
Price Statistics
The NADAC for COTEMPLA XR-ODT 17.3 MG TABLET has been published 455 times since Jan 17, 2018, and over the history we have for it it has risen 74.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.8934 per EA |
|---|---|
| All-time high | $18.0380 (Aug 12, 2026) |
| All-time low | $10.2304 (Jan 17, 2018) |
| 52-week high | $18.0380 |
| 52-week low | $17.0932 |
| Median price | $14.3192 |
| Average price | $14.4508 |
| Largest weekly change | +13.2% (Jan 1, 2020) |
| Weeks tracked | 455 |
| Tracking since | Jan 17, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylphenidate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Neos Therapeutics Brands, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COTEMPLA XR-ODT 17.3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for COTEMPLA XR-ODT 17.3 MG TABLET, manufactured by Neos Therapeutics Brands, LLC, is $17.8934 per EA (NDC 70165020030), effective Sep 30, 2026.
How has the price of COTEMPLA XR-ODT 17.3 MG TABLET changed over time?
Over the history we have for it, the NADAC for COTEMPLA XR-ODT 17.3 MG TABLET has risen 74.9%. It has been tracked across 455 weekly CMS publications since Jan 17, 2018.
What are the highest and lowest recorded NADAC prices for COTEMPLA XR-ODT 17.3 MG TABLET?
Since Jan 17, 2018, the NADAC for COTEMPLA XR-ODT 17.3 MG TABLET has ranged from a low of $10.2304 (Jan 17, 2018) to a high of $18.0380 (Aug 12, 2026), with a median of $14.3192 per EA.
Are there cheaper alternatives to COTEMPLA XR-ODT 17.3 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of COTEMPLA XR-ODT 17.3 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures COTEMPLA XR-ODT 17.3 MG TABLET?
COTEMPLA XR-ODT 17.3 MG TABLET (NDC 70165020030) is labeled by Neos Therapeutics Brands, LLC, and CMS classifies it as a brand product.